The pressure/volume relationship during dobutamine stress echocardiography in transplanted heart: comparison with quality of life and coronary anatomy by unknown
CARDIOVASCULAR 
ULTRASOUND
Minardi et al. Cardiovascular Ultrasound 2012, 10:44
http://www.cardiovascularultrasound.com/content/10/1/44RESEARCH Open AccessThe pressure/volume relationship during
dobutamine stress echocardiography in
transplanted heart: comparison with quality
of life and coronary anatomy
Giovanni Minardi1, Giordano Zampi1*, Amedeo Pergolini1, Giovanni Pulignano1, Massimiliano Scappaticci2,
Francesca Moschella Orsini1, Gaetano Pero1, Paola Lilla Della Monica1, Giovanni Cioffi3 and Francesco Musumeci1Abstract
Background: Cardiac allograft vasculopathy (CAV) is a major late complication in cardiac transplant recipients and
has a relevant impact on outcome of these patients. Aims of this study: to compare, in cardiac transplant recipients
patients, the diagnostic value of pressure/volume relationship (ESPVR) during dobutamine stress echocardiography
(DSE) for coronary artery disease, assessed by Multislice Computed Tomography (MSCT), and by coronary
angiography (CA). We also analyzed any possible relationship between ESPVR and the Health Related Quality of Life
of the patients (HRQoL), evaluated by SF–36 questionnaire.
Methods: 25 consecutive patients underwent DSE within 24 hours after MSCT coronary angiogram and then they
underwent CA. The HRQoL questionnaire was administered to the patients in the settings of DSE. They were
followed-up for 6 months.
Results: DSE has a sensitivity in detecting CAV of 67%, specificity of 95%, positive predictive value of 67% and
negative predictive value of 95%; DSE with ESPVR has a sensitivity of 100%, specificity of 95%, positive predictive
value of 75%, negative predictive value of 100%; MSCT has a sensitivity of 100%; specificity of 82%; positive
predictive value of 43%; negative predictive value of 100%. Htx recipients with a flat-biphasic ESPVR, although
asymptomatic, perceived a worst HRQoL compared with the up-sloping ESPVR population, and this is statistically
significant for the general health (p 0.0004), the vitality (p 0.0013) and the mental health (p 0.021) SF-36 subscale.
Conclusions: Evaluation with DSE and ESPVR is accurate in the clinical control of heart transplant recipients
reserving invasive evaluation only for patients with abnormal contractility indexes.
Keywords: Dobutamine stress echocardiography, Cardiac allograft vasculopathy, Coronary angiography, Multislice
computed tomographyBackground
Cardiac allograft vasculopathy (CAV) is a major late com-
plication in cardiac transplant recipients. This disease is
insidious and usually gives no clues until heart failure,
myocardial infarction, or death occurs [1-4]. Routine
evaluation with coronary angiography and/or intravascu-
lar ultrasound are not a reasonable approach because* Correspondence: giordano.zampi@alice.it
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reproduction in any medium, provided the orinvasive and potentially harmful, expensive, and some-
times inaccurate. Less invasive methods in identifying
patients at increased risk of CAV haves been tested in re-
cent studies [5-8]; Multislice Computed Tomography
(MSCT) and dobutamine stress echocardiography (DSE)
have shown to be accurate diagnostic techniques for this
harmful condition [9,10].
In recent years, Bombardini and co-workers [11-13]
demonstrated that the left ventricular (LV) end-systolic
pressure-volume relationship (ESPVR) was a prognos-
tically useful noninvasive index of global contractility,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with negative exercise [11] and DSE [13].
The primary aims of this study was to assess, in car-
diac transplant recipients patients, the accuracy of
ESPVR (stated as index of LV myocardial contractility)
in detecting CAV searched by MSCT and coronary angi-
ography. We also analyzed any possible relationship
between ESPVR and quality of life in these patients.Methods
Study patients
From September 2011 to January 2012, asymptomatic
heart transplanted recipients from the Heart Transplant
Center of San Camillo - Forlanini Hospital in Rome
were consecutively enrolled.
Study population comprised 25 patients who under-
went DSE within 24 hours after MSCT coronary
angiogram and, if the results of almost one of the two
non-invasive diagnostic technique was positive, the patient
underwent coronary angiography within 1 week after the
tests, and if negative within 2 months. All patients were in
sinus rhythm and on optimal and maximal tolerated
pharmacological therapy, according to current guidelines
for treatment and management of cardiac transplant [14].
Ongoing medical therapy was kept unchanged at the time
of the stress test. No patients had implantable cardioverter-
defibrillators or pacemakers. The exclusion criteria were:
less than 12 months since transplant, iodinated contrast
media allergy, signs or symptoms of CAV and New York
Heart Association (NYHA) functional class IV. The
sonographers were unaware of the results of the MSCT
and of the coronary angiography.
The study complies with the Declaration of Helsinki.
All patients gave written informed consent when they
underwent stress echocardiography. When patients signed
the consent forms, they also authorized physicians to use
their clinical data according to Italian law.Quality of life assessment
Quality of life has been assessed with the standard
form of the SF–36 Health Survey (Version 1) [15],
which has been used in a number of previous studies
of organ-transplant candidates and recipients [16], with
findings suggesting excellent validity and reliability.
This test includes multiple-item scales to measure the
following 8 health-related aspects: physical function
(PF); role-physical (RP); bodily pain (BP); general
health perceptions (GH); vitality (VT); social function
(SF); role-emotional (RE); and mental health (MH).
Scores were transformed into scores from 0 to 100, based
on SF–36 scoring algorithms, where higher scores reflect
better health [17]. SF-36 questionnaire was administered
to the patients in the settings of DSE.Stress protocol
Two-dimensional echocardiography and 12-lead electro-
cardiographic monitoring were performed in combination
with high dose (up to 40 mcg/kg/min) dobutamine.
Atropine infusion was considered if 85% of maximal heart
rate wasn’t achieved at the end of DSE. During the pro-
cedure, blood pressure and the electrocardiogram were
recorded each minute. Only representative cycles with op-
timal endocardial visualization were measured and the
average of three measurements was taken. Images were
acquired at baseline and at each 10-beat frequency increase
during stress. LV volumes and ejection fraction were mea-
sured at rest and at each step using biplane Simpson rule.
All volume measures were normalized by dividing by body
surface area. Regional wall motion was assessed according
to the recommendations of the European Society of
Echocardiography from 1 (normal) to 4 (dyskinetic) in a
16-segment model of the left ventricle [18]. The blood
pressure recording was made using a sphygmomanometer
and the diaphragm of a standard stethoscope [19].
Non-echocardiographic criteria for ending the test
were peak dobutamine, achievement 85% of target heart
rate, (determined according to the equation: 220 – age),
intolerable chest pain, excessive increase in blood pres-
sure (defined as systolic blood pressure > 220 mm Hg;
diastolic blood pressure > 120 mm Hg), hypotension
(relative or absolute: > 30 mm Hg decrease in blood pres-
sure), sustained supraventricular arrhythmias (supraven-
tricular tachycardia or atrial fibrillation), ventricular
arrhythmias (ventricular tachicardia, frequent, polymorph-
ous premature ventricular beats), bradyarrhythmias. A
maximal test was defined by the achievement of 85% of
age-predicted maximal heart rate.
End-systolic pressure–volume determination
ESPVR was defined as the ratio of the systolic blood
pressure (SBP)/end-systolic volume index (ESVi). The
slope of the relationship was calculated as the ratio be-
tween SBP/ESVi and heart rate increase (from baseline
to peak stress). The ESPVR was defined up-sloping when
dobutamine-induced SBP/ESVi increase was higher than
25th percentile values of the entire study group, flat
when below the 25th percentile values; biphasic, with an
initial up-sloping followed by a later down-sloping trend,
when peak dobutamine SBP/ESVi was lower than inter-
mediate stress values [20,21]. The critical heart rate was
defined as the heart rate at which SBP/ESVi reached the
maximum value during progressive increase in heart
rate. In biphasic pattern, the critical heart rate was the
heart rate beyond which SBP/ESVi declined by 5%.
Clinical follow-up
The patients were observed prospectively for 6 months
with regular monthly outpatient visits. Adverse
Table 1 Characteristics of the study patients
Patients 25
Age (years) 58 ± 12
Gender (M/F) 21/4 (84/16%)
Years from Htx 8.5 ± 7
BMI (kg/m2) 27.4 ± 4.2
eGFR - CKD-EPI (ml/min) 61.7 ± 25.8
Hypertension 19 (76%)
Diabetes 10 (40%)
Previous Smoking Habits 17 (68%)
Metabolic Syndrome 8 (32%)
Familiarity for CVD 12 (48%)
Dyslipidemia 12 (48%)
Atypical Chest Pain 6 (24%)
PTCA (post HTx) 3 (12%)







Post Ischemic Dilated CM 9 (36%)
Idiopathic Dilated CM 11 (44%)
End-Stage Hypertrophic CM 1 (4%)
Non-Compactation CM 1 (4%)
Peripartum CM 1 (4%)
Dilated CM in Becker Dystrophy 1 (4%)
Post Myocarditis Dilated CM 1 (4%)
BMI, Body mass index; eGFR, Estimated Glomerular Filtration Rate; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; CVD, cardiovascular
disease; Htx, heart transplantation; NYHA, New York Heart Association; CM,
Cardiomyopathy.
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sidered were death, non-fatal acute myocardial infarc-
tion, and heart failure.
Statistics
Statistical analyses were performed using SPSS, version
17.0 (SPSS, Inc., Chicago, IL) for Windows. We assumed
the coronary angiography as the reference standard for
the identification of CAV. Results of MSCT and DSE
(with and without ESPVR) were compared to the coron-
ary angiography’s ones in order to evaluate diagnostic
accuracy of the non-invasive tests. Distribution of rele-
vant variables was summarized using frequencies, means,
medians and standard errors (SEs), as appropriate. Uni-
variate analysis was performed to compare the differ-
ences between ESPVR with continuous variables, using
Fisher’s exact test and the Student unpaired t-test. Differ-
ences between groups and quality of life measures were
analyzed using tests for non-normally distributed sam-
ples, as appropriate. To address the potential problem of
error rate with multiple testing, Bonferroni–Holm
adjustments were performed. All probability values were
obtained using 2-sided analyses; p ≤ 0.05 was considered
statistically significant for all analyses.
Results
The baseline clinical and echocardiographic characteris-
tics of the study patients are reported in Table 1. Most
of patients were males in NYHA functional class I-II
with a high prevalence of history of hypertension. Rest-
ing LV ejection fraction was normal in all patients.
About three fourth of patients received beta-blockers
and 23 of 25 took statins and acetyl salicylic acid. In the
study protocol 3 patients with percutaneous translum-
inal coronary angioplasty (PTCA) procedure with stent
deployment after HTx were enrolled: 2 of them
underwent procedure, about 5 years before, because
of a ST-elevation-Myocardial Infarction (door-to-bal-
loon < 90 min) without any residual stenosis nor
myocardial damages, and 1 of them due to a signifi-
cant coronary stenosis founded 7 years before during
a follow-up coronary angiography.
Feasibility and tolerability of high-dose DSE
Near the totality of patients (22/25 = 88%) reached the
maximal dose of DSE (40 mcg/kg/min); in 3 patients
dobutamine infusion was stopped at 30 mcg: in 1 patient
because of the achievement of 85% of age-predicted
maximal heart rate, and in 2 patients because of
excessive increase in blood pressure.
5 patients (20%) achieved age-predicted maximal heart
rate at the end of DSE, whilst the remaining 20 patients
achieved 85% of maximum predicted heart rate.
During dobutamine infusion, non-sustained ventriculartachycardia was observed in 1 patient; this complication
was well tolerated, not causing the premature interruption
of the test. Hemodynamic and echocardiographic
responses to DSE are described in Table 2.
Relation among DSE, DSE + ESPVR, MSCT and CA
At the coronary angiography 3 out of 25 patients (12%)
had significant coronary stenosis: a 80% narrowed
proximal left anterior descending artery was found in
all the 3 patients.
The DSE resulted positive in 2 patients with positive
coronary angiography and in 1 out of 25 patients with
negative coronary angiography; 1 patient with CAV had
a negative test (sensitivity 67%; specificity 95%; positive
predictive value 67%; negative predictive value 95%).
The ESPVR was abnormal (flat or biphasic) in 4
patients and normal (i.e. steep up-sloping) in 21
patients. The biphasic response was present in all the
Table 2 Echocardiographic data and force-frequency
relationship during dobutamine echo
Left Ventricular EDV (ml) 108 ± 28
Left Ventricular ESV rest (ml/m2) 23 ± 8
Left Ventricular ESV peak (ml/m2) 11 ± 6
Systolic Pressure rest (mmHg) 127 ± 13
Systolic Pressure peak (mmHg) 160 ± 27
SP/ESV index (rest) 6.22 ± 2.53
SP/ESV index (peak) 17.03 ± 7.88
ESPVR slope (χ 10-2) 21.1 ± 7.3
Δ peak – rest (mmHg/ml) 10.85 ± 6.9
Heart rate rest (b.p.m.) 82 ± 6
Heart rate peak (b.p.m.) 129 ± 15
Left Ventricular Ejection fraction (rest, %) 59 ± 8
Left Ventricular Ejection fraction (peak, %) 72 ± 9
Double product (rest) 10437 ± 1396
Double product (peak) 20838 ± 3481
Ischaemia during Dobutamine, n (%) 3 (12%)
Flat-biphasic ESPVR during Dobutamine, n (%) 4 (16%)
Critical Heart Rate (b.p.m.) 123 ± 17
Dobutamine dose 40 μg, n (%) 22 (88%)
Dobutamine dose 30 μg, n (%) 3 (12%)




Mycophenolate mofetil 14 (56%)
Cortisone 3 (12%)









ACE-I: angiotensin converting enzyme inhibitor; ARBS: Angiotensin II Receptor
Blockers; EDV: end diastolic volume; ESPVR: end-systolic pressure/volume ratio;
ESV: end systolic volume; SP, systolic pressure.
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in 1 out of 25 patients with negative coronary
angiography (sensitivity 100%; specificity 95%; posi-
tive predictive value 75%; negative predictive value
100%) (Figure 1).
The MSCT showed significant coronary artery stenosis
in 7 out of 25 patients: all the 3 patients with CAV were
correctly identified (showing the same results of the
coronary angiography), but 4 patients with positive
MSCT had normal coronary arteries at the coronaryangiography (sensitivity 100%; specificity 82%; positive
predictive value 43%; negative predictive value 100%).
Comparison of quality of life ratings with normative data
Patients’ quality of life self-ratings were compared with
age- and gender-adjusted norms [17]. Based on norma-
tive data, HTx recipients with up-sloping ESPVR per-
ceived a better quality of life for 4 of 8 SF-36 subscales
compared with the normative population. Htx recipients
with a flat-biphasic ESPVR, perceived a worset quality of
life compared with the up-sloping ESPVR population, and
this was statistically significant for the GH (Flat-biphasic
25.25 ± 19.2 vs up-sloping 60 ± 15, p 0.0004), the VT
(Flat-biphasic 35 ± 9 vs up-sloping 66 ± 16, p 0.0013)
and the MH (Flat-biphasic 49 ± 24.7 vs up-sloping
76.4 ± 19.6, p 0.021) SF-36 subscale (Figure 2).
Quality of life was independent of principal demo-
graphic variables such as age, gender and years from
transplantation (Table 3).
Results of 6 months follow-up
At the end of the follow-up no patient died; during the
6 months of follow-up, 2 patients, both with positive
DSE and flat-biphasic ESPVR, had cardiac events.
1 patient, with coronary stenosis treated with stenting,
experienced, two months later, an exacerbation of
chronic heart failure solved ambulatory by increasing
diuretics doses.
1 patient, with negative MSCT and CA but positive
DSE and flat-biphasic ESPVR, experienced, four months
later, an acute heart failure episode due to acute heart
rejection diagnosed by endo-myocardial biopsy. The pa-
tient was hospitalized and treated with a short course of
high-dose corticosteroids, a calcineurin inhibitor and an
anti-proliferative agent; thanks to this treatment, the
patient survived to the episode.
Discussion
Differently from general population of patients with
coronary artery disease, there are only few studies com-
paring the accuracy of DSE, MSCT and coronary angiog-
raphy for detecting CAV in cardiac transplant recipients
[10]. The uniqueness of our study is that all our
patients underwent the three techniques, and intro-
duced in the DSE protocol the valuation of the
ESPVR for diagnosing CAV. At our knowledge, in-
deed, this is the first study in which ESPVR is used
to assess LV contractility, coronary anatomy and
quality of life in a population of asymptomatic heart
transplant recipients. The results of the present study
are broadly consistent with the previous evidences
suggesting that the challenge of inotropic reserve
with catecholamine infusion is useful to unmask
depressed contractile reserve in a left ventricle with
Figure 1 Plot of the force–frequency relationship in Group 1 (flat-biphasic ESPVR, left panel) and Group 2 (up-sloping-ESPVR,
right panel).
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original, this technique significantly improves the
prediction of CAV in comparison with MSTC, reducing
the risk of useless invasive interventions.Figure 2 Comparison of quality of life (SF 36) between heart transpla
age-adjusted Italian population Normative value (PF: physical functio
perceptions; VT: vitality; SF: social function; RE: role-emotional; MH: aDifficulty in detecting and treating CAV remains the
major limiting factor for survival after heart transplantation.
The disease is silent in most of cases mainly because of
cardiac denervation.nted patient with Flat-biphasic ESPVR, up-sloping ESPVR and
n; RP: role-physical; BP: bodily pain; GH: general health
nd mental health).
Table 3 Statistics correlations between demographic and echocardiographic characteristics of the study population
and the SF-36 items
PF RP BP GH VT SF RE MH
Demographics
Age (years) p 0.27 p 0.09 p 0.7 p 0.13 p 0.20 p 0.73 p 0.12 p 0.89
Gender (M/F) p 0.06 p 0.19 p 0.12 p 0.46 p 0.25 p 0.22 p 0.49 p 0.21
TimeHTx p 0.22 p 0.29 p 0.92 p 0.78 p 0.45 p 0.24 p 0.19 p 0.92
Echocardiographic variable
Flat-bifasic p 0.27 p 0.16 p 0.67 p 0.000^ p 0.001^ p 0.22 p 0.21 p 0.02*
TimeHTx, time from heart transplant; * p value < 0.05; ^ p value < 0.01.
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the anatomic one: coronary angiography CA is still the
reference standard for diagnosing CAV, in spite of its
invasive nature not free from complications and the
exposure to ionizing radiation and to iodinated contrast
media given to patients taking immunosuppressive
medications. Up today, many centers perform annual
evaluations to establish the presence and severity of
CAV after heart transplantation [22].
Another relevant anatomic modality to detecting CAV,
although non-invasive, is MSCT. In 2000, Knollmann and
co-workers [20] compared, in 112 heart transplant recipi-
ents, the electron-beam CT features of coronary arteries
with those of biplane coronary angiography and intracor-
onary ultrasound. They found that electron-beam CT had
a sensitivity of 94%, a specificity of 79%, a positive predict-
ive value of 43%, and a negative predictive value of 99% for
detecting coronary stenosis. Similar results, comparing car-
diac multi-detector computed tomography angiography
and coronary angiography, were found by von Ziegler and
co-workers [21]. From these data appear a high negative
predictive value and an unsatisfactory positive predictive
value of this diagnostic tool. Our results are in line with
those previously reported that lead to overestimate the cor-
onary disease with the clinical implication of an inappropri-
ate request for coronary angiography, which implies the use
of nephrotoxic agents. As expected, many heart transplant
recipients have chronic kidney disease due to cyclosporine
or other immunosuppressive therapy: in our population
88% of the patients were treated with cyclosporine. It is a
very important problem that the cardiologists have to think
about when prescribe aMSCT.
Moreover, we analyzed the presence of any possible
relationship between ESPVR and quality of life. Theoret-
ically a loss of contractile reserve could carry to a worse
physical activity: it can be caused by a classic ischemic
mechanism, due to a reduced blood supply in situations
of increased cardiac output (i.e. catecholamine infusion),
or by an inflammatory response as in the heart
transplant rejection. Both mechanisms cannot be
identified either by CA or by MSCT, and a functional
test is requested to reveal whether a reducedfunctional capacity may be associated with a latent
ventricle dysfunction.
Our results seem confirm this hypothesis: patients with
flat-biphasic ESPVR, indeed, have lower scores in all the 8
subscales of the SF-36 questionnaire, and this is statisti-
cally significant for general health, mental health and
vitality. Also in that single patient with flat-biphasic
ESPVR and negative coronary angiography, the results of
the SF-36 were coherent with the inotropic reserve found.Study limitations
Our study has several limitations.
Calculation of the ESPVR requires measurement of
the LV pressure at the end-systole. Because only non-
invasive measurements were available, cuff systolic
pressure was substituted for end-systolic pressure.
The overall patient population was small, thus limiting
the generalizability of our findings. Studies with a larger
sample size and longer follow-up are warranted.
Finally, in all patients on β-blocking agents, therapy
was kept unchanged and may have influenced, at
least in part the results. However, the optimal dose
of dobutamine to assess contractility and recognize
CAV is not defined and it did not appear ethical to
withdraw a life-saving therapy.Conclusions
The evaluation of ESPVR with DSE may be a safe and
feasible strategy for the clinical control of heart transplant
recipients during the time. It seems to provide an accurate
assessment of coronary artery anatomy and function and a
suitable selection of candidates to invasive evaluation.
ESPVR evaluation may also be helpful for explaining a
worsen quality of life referred by some patient when it is
associated with the development of cardiac abnormalities
during physical exercise undetectable by most of the
available invasive and non-invasive diagnostic techniques
for CAV.
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